Johnson & Johnson Innovation announced a collaboration with the Shanghai Municipal Government, Pudong New Area Government, and Shanghai Pharma Engine to launch a new Johnson & Johnson Innovation, JLABS in Shanghai China. The 4,400-square-meter facility will be located in Shanghai's Zhangjiang Hi-Tech Park and will open in Q2 2019.
JLABS @ Shanghai will be the first JLABS location established outside of North America and will accommodate up to 50 life science and healthcare startups, both single entrepreneurs and larger companies, focused on innovations across the entire healthcare spectrum, including pharmaceuticals, medical devices and consumer. JLABS @ Shanghai will provide resident innovators with a capital efficient and flexible platform including an extensive network that will enable them to accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients in China and around the world.
"We are excited about the launch of JLABS @ Shanghai, which will be an integral investment in the city's life science ecosystem. It will support entrepreneurship as it relates to science and technology and strengthen our position as a global innovation hub," said Mr. Liu Qin, Deputy Inspector General, Science and Technology Commission, Shanghai Municipal Government.
The launch of JLABS @ Shanghai demonstrates Johnson & Johnson's continued commitment to enabling the best science and technology with the ambition of solving the greatest unmet medical and healthcare needs of our time. JLABS @ Shanghai builds on the successful no-strings attached JLABS model and will be the ninth JLABS location to open globally.
JLABS @ Shanghai will provide startups with many of the advantages of being part of an established innovation hub, such as access to talent and mentors, large existing firms and research universities, capital and convergence opportunities with other sectors. When complete, the 4,400-square-meter facility will include cutting-edge, modular and scalable lab space, equipment, with access to scientific, industry and capital funding experts. The space will also feature a JLABS device and digital prototype lab that will provide entrepreneurs with access to highly specialized tools as well as skill-building programs to design and develop smart health technologies.
The agreement to operate aJLABS was signed by Johnson & Johnson Innovation, Division of Johnson & Johnson (China) Investment, and Shanghai Pharma Engine.